Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Osteosarcoma 2Renal Insufficiency 1Neoplasms 1Mucositis 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Amifostine 10Cisplatin 8Radiotherapy 7Etoposide 6Cyclophosphamide 4Carboplatin 4Paclitaxel 3pegfilgrastim 2camrelizumab 2apatinib 2Mitoxantrone 2Filgrastim 2Drug Therapy 2Cytarabine 2sodium thiosulfate 1sargramostim 1pazopanib 1icotinib 1glucarpidase 1etoposide phosphate 1denileukin diftitox 1Vitamin E 1Triptorelin Pamoate 1Tocopherols 1Thiotepa 1Tegafur 1Taxes 1Surgical Procedures, Operative 1Silymarin 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Drug-Related Side Effects and Adverse Reactions × glucarpidase × Clear all
NCT05022797 2024-05-13

Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS

Fundacion CRIS de Investigación para Vencer el Cáncer

Phase 2 Terminated
3 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡